InvestSMART

Bio-Gene Technology Ltd (ASX: BGT) - Announcements

- Current share price for BGT : $0.017

ASX company news and announcements for Bio-Gene Technology Ltd (BGT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bio-Gene Technology Ltd (BGT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bio-Gene Technology Ltd (BGT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bio-Gene Technology Ltd (BGT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Results of Placement 26 May 2026 9:59AM $0.029 $0.017 fallen by 41.38%
$7 Trading Halt 22 May 2026 9:28AM $0.029 $0.017 fallen by 41.38%
$7 BGT to expand Flavocide and Qcide evaluation to Asia 21 May 2026 8:34AM $0.027 $0.017 fallen by 37.04%
$7 Key insecticide combinations patent allowed in the US 6 May 2026 9:49AM $0.038 $0.017 fallen by 55.26%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 27 Apr 2026 11:55AM $0.038 $0.017 fallen by 55.26%
$7 Investor Presentation 20 Apr 2026 9:32AM $0.038 $0.017 fallen by 55.26%
$7 Change of Auditor 14 Apr 2026 9:33AM $0.035 $0.017 fallen by 51.43%
$7 NWR Healthcare Conference Presentation 26 Mar 2026 12:20PM $0.035 $0.017 fallen by 51.43%
$7 Bio-Gene to present at NWR Healthcare Conference 20 Mar 2026 9:58AM $0.034 $0.017 fallen by 50%
$7 Sumitomo & Nakashima to launch Qcide products in Japan 16 Mar 2026 8:18AM $0.035 $0.017 fallen by 51.43%
$7 Update on Qcide Production 10 Mar 2026 9:28AM $0.035 $0.017 fallen by 51.43%
$7 Regulatory Development of Flavocide 3 Mar 2026 9:05AM $0.033 $0.017 fallen by 48.48%
$7 Appendix 4D and Half-Year Accounts 31 December 2025 24 Feb 2026 9:35AM $0.031 $0.017 fallen by 45.16%
$7 Flavocide Acute Neurotoxicity Study Underway 13 Feb 2026 9:45AM $0.031 $0.017 fallen by 45.16%
$7 Flavocide Reproductive Toxicity Study Underway 9 Feb 2026 9:31AM $0.033 $0.017 fallen by 48.48%
$7 CFO and Company Secretary Appointment/Resignation 2 Feb 2026 9:11AM $0.035 $0.017 fallen by 51.43%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:24AM $0.031 $0.017 fallen by 45.16%
$7 U.S. Department of Defense Grant Programs Advance 18 Dec 2025 8:53AM $0.023 $0.017 fallen by 26.09%
$7 Outcome of review of Continuous Disclosure Procedures 2 Dec 2025 8:21AM $0.026 $0.017 fallen by 34.62%
$7 Bio-Gene Receives $519,500 R&D Tax Incentive 25 Nov 2025 8:16AM $0.028 $0.017 fallen by 39.29%
$7 Results of Meeting 19 Nov 2025 3:42PM $0.029 $0.017 fallen by 41.38%
$7 CEO's Presentation 19 Nov 2025 2:20PM $0.029 $0.017 fallen by 41.38%
$7 Chair's Address to Shareholders 19 Nov 2025 2:18PM $0.029 $0.017 fallen by 41.38%
$7 Qcide receives organic listing status in USA 14 Nov 2025 8:19AM $0.028 $0.017 fallen by 39.29%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2025 8:17AM $0.023 $0.017 fallen by 26.09%

26 - 50 of 479 results

Page 2 of 20

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.